Lipum starts chronic inflammatory disease drug study
Lipum has started a phase 1 clinical study of SOL-116, a fully humanized antibody intended to treat certain chronic inflammatory diseases.
Source: labiotech.eu
Einar Pont News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Einar Pont. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Einar Pont Today - Breaking & Trending Today
Lipum has entered a partnership with QPS Netherlands B.V. for its first clinical trial with SOL-116
Press release: Umeå, March 9, 2022. Lipum AB announce that the company has entered into an agreement with QPS Netherlands BV for the first-in-man phase I-study of the drug candidate SOL-116.... | March 9, 2022
Source: marketscreener.com
Nasdaq Nordic: Nasdaq Stockholm Welcomes Lipum to the Nasdaq First North Growth Market
Nasdaq Nordic: Nasdaq Stockholm Welcomes Lipum to the Nasdaq First North Growth Market Stockholm, April 22, 2021 - Nasdaq (Nasdaq: NDAQ) announces that trading in Lipum AB's shares (short name LIPUM) commences today on Nasdaq First North Growth Market. The company belongs to the Health care sector. Lipum is the 39th company to be admitted to trading on Nasdaq's Nordic markets* in 2021. Lipum is a biopharmaceutical company specialized on a novel way to treat chronic inflammatory diseases. The lead candidate drug (SOL-116) is a fully humanized antibody designed to give safer and more efficacio...
Source: finanznachrichten.de